J Mater Sci Mater Med:Ti-Cu合金细胞相容性与成骨能力的体外研究

2019-06-21 不详 网络

钛植入物由于其固有的缺乏自我保护能力而容易在临床上遭受细菌相关的感染。因此,本研究开发了一种具有良好抗菌活性的新型Ti-Cu合金作为一种新型的植入材料。 体外评估Ti-Cu合金的细胞相容性和成骨活性。结果表明,在纯Ti中加入5%Cu不会对Ti-Cu合金培养的成骨细胞粘附,增殖和凋亡产生任何负面影响。 此外,Ti-Cu合金通过上调成骨相关基因表达,包括碱性磷酸酶(ALP),胶原蛋白I(Colla I

钛植入物由于其固有的缺乏自我保护能力而容易在临床上遭受细菌相关的感染。因此,本研究开发了一种具有良好抗菌活性的新型Ti-Cu合金作为一种新型的植入材料。

体外评估Ti-Cu合金的细胞相容性和成骨活性。结果表明,在纯Ti中加入5%Cu不会对Ti-Cu合金培养的成骨细胞粘附,增殖和凋亡产生任何负面影响。 此外,Ti-Cu合金通过上调成骨相关基因表达,包括碱性磷酸酶(ALP),胶原蛋白I(Colla I),骨桥蛋白(OPN)和骨钙素(OCN),可明显促进MG 63细胞的成骨分化。

综上所述,该研究结果表明,Ti-Cu合金具有很大的潜力,可用作临床应用的多功能钛植入物。

原始出处:

Liu R, Ma Z, et al., In vitro study on cytocompatibility and osteogenesis ability of Ti-Cu alloy. J Mater Sci Mater Med. 2019 Jun 19;30(7):75. doi: 10.1007/s10856-019-6277-z.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1352169, encodeId=829c1352169c9, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 23 14:23:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465415, encodeId=46f0146541571, content=<a href='/topic/show?id=662a388823e' target=_blank style='color:#2F92EE;'>#合金#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38882, encryptionId=662a388823e, topicName=合金)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81df6719716, createdName=楚秀娟, createdTime=Sun Jun 23 14:23:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609833, encodeId=c7c91609833fa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 23 14:23:00 CST 2019, time=2019-06-23, status=1, ipAttribution=)]
    2019-06-23 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1352169, encodeId=829c1352169c9, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 23 14:23:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465415, encodeId=46f0146541571, content=<a href='/topic/show?id=662a388823e' target=_blank style='color:#2F92EE;'>#合金#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38882, encryptionId=662a388823e, topicName=合金)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81df6719716, createdName=楚秀娟, createdTime=Sun Jun 23 14:23:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609833, encodeId=c7c91609833fa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 23 14:23:00 CST 2019, time=2019-06-23, status=1, ipAttribution=)]
    2019-06-23 楚秀娟
  3. [GetPortalCommentsPageByObjectIdResponse(id=1352169, encodeId=829c1352169c9, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 23 14:23:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465415, encodeId=46f0146541571, content=<a href='/topic/show?id=662a388823e' target=_blank style='color:#2F92EE;'>#合金#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38882, encryptionId=662a388823e, topicName=合金)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=81df6719716, createdName=楚秀娟, createdTime=Sun Jun 23 14:23:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609833, encodeId=c7c91609833fa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 23 14:23:00 CST 2019, time=2019-06-23, status=1, ipAttribution=)]